



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Phone : +91 92280 16100 - 03 | +91 79 2646 8353, 4002 3839 | Fax : +91 79 26404961
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : info@ishitadrugs.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.com



Date: 14th August, 2017

To,
The Company Section
The Bombay Stock Exchange
Phiroz Jijibhoy Towers
Dalal Street, Bombay- 400 001

Security Code: 524400

Dear Sir,

Sub: Outcome of Board Meeting held on 14th August, 2017 pursuant to Regulation 30 of SEBI(LODR) Regulation, 2015.

This is to inform you that the Board of directors of the Company at its meeting held today on Monday, the 14th Day of August, 2017 have

1. Approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter ended on 30th June, 2017 pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015.

Hope the enclosed papers are in accordance with requirements. Please take the same on your records and oblige. Please do the needful.

Thanking You.

For, Ishita Drugs & Industries Ltd.

Authorised Signatory



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054
D & B D-U-N-S Number - 65-018-0359

KISHOR GOYAL & CO.

Chartered Accountants

Kishor Goyal

B.Com.(Hons); F.C.A.;DISA (ICAI); DIRM (ICAI)

To,
The Board of Directors,
Ishita Drugs & Industries Ltd,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LTD** for the period ended **30th June, 2017** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligations and Disclosure Requirements) Regulation,2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing of Obligations and Disclosure Requirements) Regulation,2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
KISHOR GOYAL & CO.
Chartered Accountants



Kishor Goyal
Partner
M.No.047286
Date: 14/08/2017
Place: Ahmedabad



305, P.B.Parekh Tower, Opp.Vanijya Bhavan, Kankaria Road, Ahmedabad-380022.
Ph. : 25453986, 25452196, 30285657 (R) 25399515(M) :9377750059, 9898250057
E-mail : goyalkishor@yahoo.com

ISHITA DRUGS AND INDUSTRIES LIMITED
 CIN: L24231GJ1992PLC017054
 Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
 Ahmedabad – 382170
 Website: www.ishitadrugs.com
 Contact: +91 9228016100

Financial Results for the Quarter Ended June 30, 2017

Particulars		Amount in Lacs	
		Quarter Ended	
		3 Months Ended 30-Jun-17	3 Months Ended 30-Jun-16
PART I			
1	INCOME		
	Revenue from Operations	141.22	157.96
	Other Income	-2.91	2.51
	Total Income	138.31	160.47
2	EXPENSES		
	(a) Cost of Material Consumed	75.87	100.86
	(b) Purchase of Stock-In-Trade	0	8.74
	(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-4.42	-2.79
	(d) Employee Benefit Expense	19.92	15.38
	(e) Finance Cost	0.94	0.49
	(f) Depreciation, Depletion and Amortisation Expense	4	3.85
	(g) Other Expense	35.11	29.46
1			
2			
3			
4			
5			
	Total Other Expenses	35.11	29.46
	Total Expenses	131.42	155.99
3	Total Profit before Exceptional Items and Tax	6.89	4.48
4	Exceptional Items	0	0
5	Total Profit before Tax	6.89	4.48
6	Tax Expense		
7	Current Tax	1.89	1.00
8	Deferred Tax	0	0
9	Total Tax Expenses	1.89	1.00
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	5.00	3.48
12	Profit / (Loss) from discontinued operations before tax	0	0
13	Tax Expenses of discontinued operations	0	0
14	Net Profit / (Loss) from discontinued operations after tax	0	0
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0	0
16	Total Profit / (Loss) for the period	5.00	3.48
17	Other Comprehensive Income net of Taxes	0	0
18	Total Comprehensive Income for the Period	5.00	3.48
19	Total profit or loss attributable to		
	Profit or loss, attributable to owners of parents	0	0
	Total Profit or loss, attributable to non-controlling interests	0	0
20	Total comprehensive income for the period attributable to		
	Comprehensive Income for the period attributable to the owners of parents	0	0
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0	0
21	Details of Equity Share Capital		
	Paid-Up Equity Share Capital	299.03	299.03
	Face Value of Equity Share Capital	10	10
22	Details of Debt Securities		
	Paid-Up Debt Capital	0	0
	Face Value of Debt Securities	0	0
23	Reserves Excluding Revaluation Reserves	0	0
24	Debenture Redemption Reserve	0	0
25	Earnings Per Share		
(i)	Earnings Per Share for continuing operations		

Jaydeep Agrawal




	Basic Earnings / (Loss) per share from continuing operations	0.17	0.12
	Diluted Earnings / (Loss) per share from continuing operations	0.17	0.12
(ii)	Earnings Per Share for discontinued operations		
	Basic Earnings / (Loss) per share from discontinued operations	0	0
	Diluted Earnings / (Loss) per share from discontinued operations	0	0
(iii)	Earnings per Equity Share		
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.17	0.12
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.17	0.12
26	Debt Equity Ratio*	0	0
27	Debt Service Coverage Ratio*	0	0
28	Interest Service Coverage Ratio*	0	0
* The Company has no long term debt as on date			

The Company adopted Indian Accounting Standards (IndAS) from April 1, 2017 as per road map released by Ministry of Corporate Affairs (MCA). Reconciliation of Net Profit after tax as previously reported under Indian GAAP and IndAS for the quarter ended June 30, 2016 is as follows:

Description	30-Jun-16
	Unaudited
Net Profit as per Previous Indian GAAP	3.48
Net Profit as per IndAS	3.48

NOTES

- The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 14, 2017.
- The Limited Review of the results has been completed by the Statutory Auditors of the Company.
- As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
- The financial results for the quarter ended 30th June, 2016 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
- Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
- Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

		For, ISHITA DRUGS AND INDUSTRIES LIMITED
		
		JAGDISH AGRAWAL
Place	Ahmedabad	MANAGING DIRECTOR
Date	14-Aug-17	DIN: 01031687

